Lodestar Investment Counsel Lowered Bristol Myers Squibb (BMY) Position; Fluidigm (FLDM) Sentiment Is 0.71

June 20, 2017 - By Louis Casey

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The company has market cap of $105.54 million. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. It currently has negative earnings. The Company’s products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits , and assays and reagents.

Lodestar Investment Counsel Llc decreased Bristol Myers Squibb (BMY) stake by 15.78% reported in 2016Q4 SEC filing. Lodestar Investment Counsel Llc sold 23,538 shares as Bristol Myers Squibb (BMY)’s stock declined 1.04%. The Lodestar Investment Counsel Llc holds 125,589 shares with $7.34 million value, down from 149,127 last quarter. Bristol Myers Squibb now has $91.27B valuation. The stock increased 1.40% or $0.76 during the last trading session, reaching $55.22. About shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since June 20, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on July, 27. They expect $0.73 EPS, up 5.80% or $0.04 from last year’s $0.69 per share. BMY’s profit will be $1.21B for 18.91 P/E if the $0.73 EPS becomes a reality. After $0.84 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -13.10% negative EPS growth.

Since February 27, 2017, it had 1 buy, and 6 selling transactions for $9.91 million activity. The insider ANDREOTTI LAMBERTO sold $1.81M. LEUNG SANDRA sold $5.27M worth of Bristol-Myers Squibb Co (NYSE:BMY) on Friday, March 3. Another trade for 12,000 shares valued at $681,240 was made by Samuels Theodore R. II on Monday, February 27. On Wednesday, March 15 the insider Caldarella Joseph C sold $463,779. Schmukler Louis S had sold 15,000 shares worth $851,220 on Tuesday, March 14.

Investors sentiment decreased to 0.97 in Q4 2016. Its down 0.16, from 1.13 in 2016Q3. It fall, as 86 investors sold BMY shares while 529 reduced holdings. 126 funds opened positions while 468 raised stakes. 1.14 billion shares or 1.92% more from 1.12 billion shares in 2016Q3 were reported. Triangle Secs Wealth Management has invested 1.48% in Bristol-Myers Squibb Co (NYSE:BMY). 117,492 are owned by Osborne Partners Capital Management Ltd. Marietta Investment Partners Lc holds 0.21% or 10,300 shares. Fukoku Mutual Life Ins has invested 1% in Bristol-Myers Squibb Co (NYSE:BMY). Td Asset Mngmt holds 0.11% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 1.11M shares. Natixis Asset Mngmt owns 16,491 shares for 0.09% of their portfolio. Bluecrest Capital Mngmt reported 28,500 shares. Tiaa Cref Fsb Mo accumulated 129,929 shares. Nippon Life Americas has invested 1.65% in Bristol-Myers Squibb Co (NYSE:BMY). Davenport And Limited Liability Corp reported 0.97% stake. Concert Wealth Management has 0.48% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 36,893 shares. First Eagle Inv Management Ltd Company holds 11,529 shares. Rothschild Invest Il reported 71,571 shares. Johnson Financial Group holds 25,708 shares or 0.24% of its portfolio. Mechanics Financial Bank Trust Department holds 1.81% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 128,091 shares.

Among 17 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 7 Hold. Therefore 41% are positive. Bristol-Myers Squibb Company had 37 analyst reports since July 28, 2015 according to SRatingsIntel. Morgan Stanley downgraded the shares of BMY in report on Friday, August 5 to “Equal-Weight” rating. On Monday, May 9 the stock rating was maintained by Credit Suisse with “Outperform”. Barclays Capital maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Friday, September 9. Barclays Capital has “Equal-Weight” rating and $65 target. Societe Generale initiated the shares of BMY in report on Wednesday, April 6 with “Sell” rating. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, April 5 report. The stock has “Underweight” rating by Piper Jaffray on Monday, August 24. On Thursday, July 14 the stock rating was maintained by Jefferies with “Hold”. BMO Capital Markets downgraded the stock to “Market Perform” rating in Monday, January 25 report. The firm has “Buy” rating given on Tuesday, September 20 by Citigroup. UBS maintained Bristol-Myers Squibb Co (NYSE:BMY) on Friday, August 19 with “Buy” rating.

Since January 1, 0001, it had 2 buys, and 1 insider sale for $44,900 activity.

The stock increased 3.01% or $0.11 during the last trading session, reaching $3.77. About shares traded. Fluidigm Corporation (FLDM) has declined 36.51% since June 20, 2016 and is downtrending. It has underperformed by 53.21% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: